公开(公告)号：US09765107B2

公开(公告)日：2017-09-19

申请号：US14899008

申请日：2014-06-16

Applicant: Merck Sharp & Dohme Corp.

Inventor： Stephane Bogen ,  Vinay Girijavallabhan ,  Quang Truong ,  Ping Chen ,  Frank Bennett ,  Angela Kerekes ,  Qun Dang ,  David B. Olsen ,  Ian Davies

IPC: A01N43/04 ,  A61K31/70 ,  C07H19/10 ,  A61K45/06 ,  A61K31/661 ,  C07F9/6558 ,  C07F9/6574 ,  C07H19/11 ,  A61K31/7072 ,  A61K31/7068 ,  A61K31/706 ,  A61K31/7064

CPC classification number: C07H19/10 ,  A61K31/661 ,  A61K31/706 ,  A61K31/7064 ,  A61K31/7068 ,  A61K31/7072 ,  A61K45/06 ,  C07F9/65586 ,  C07F9/65744 ,  C07H19/11 ,  A61K2300/00

Abstract: The present invention relates to Cyclic Phosphonate Substituted Nucleoside Derivatives of Formula (I): (structure) and pharmaceutically acceptable salts thereof, wherein B, X, R1, R2 and R3 are as defined herein, as well as to compositions and methods of using the Cyclic Phosphonate Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.

公开(公告)号：US20170197989A1

公开(公告)日：2017-07-13

申请号：US15323989

申请日：2015-07-09

Applicant: Alexander PASTERNAK ,  Ian DAVIES ,  Fa-Xiang DING ,  Jinlong JIANG ,  Shuzhi DONG ,  Xin GU ,  Takao SUZUKI ,  Joseph P. VACCA ,  Zhifa PU ,  Shouning XU ,  Merck Sharp & Dohme Corp.

Inventor： Alexander Pasternak ,  Ian Davies ,  Fa-Xiang Ding ,  Jinlong Jiang ,  Shuzhi Dong ,  Xin Gu ,  Takao Suzuki ,  Joseph P. Vacca ,  Zhifa Pu ,  Shouning Xu

IPC: C07D519/00 ,  A61K31/4745 ,  A61K31/4375 ,  A61K31/435

CPC classification number: C07D519/00 ,  A61K31/435 ,  A61K31/4375 ,  A61K31/4745 ,  A61K45/06

Abstract: The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

公开(公告)号：US09457039B2

公开(公告)日：2016-10-04

申请号：US14436687

申请日：2013-10-11

Applicant: Merck Sharp & Dohme Corp.

Inventor： Vinay Girijavallabhan ,  Stephane Bogen ,  Weidong Pan ,  Qun Dang ,  Ian Davies

IPC: C07H19/12 ,  C07H19/23 ,  C07D487/04 ,  A61K31/706 ,  A61K31/53 ,  A61P31/14 ,  A61K45/06 ,  A61K31/7056 ,  A61K38/21 ,  C07H7/06

CPC classification number: A61K31/706 ,  A61K31/7056 ,  A61K38/21 ,  A61K45/06 ,  C07D487/04 ,  C07H7/06 ,  A61K2300/00

Abstract: 2′-disubstituted substituted nucleoside derivatives of formula (I) and pharmaceutically acceptable salts thereof are disclosed: (1), wherein A is N3 or NH2 and X, Y, R1, R2, R3, R4, R5 and R18 are as defined herein. Compositions comprising at least one 2′-disubstituted nucleoside derivative, and methods of using the 2′-disubstituted nucleoside derivatives for treating or preventing HCV infection in a patient are disclosed.